medicines
-
12-Dec-2018 PhRMA
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
-
12-Dec-2018 Public Citizen
TLCAN 2.0: Acuerdo Estados Unidos-México-Canadá. Capítulo 20: disposiciones de patentes relacionadas con productos farmacéuticos
El capítulo de propiedad intelectual del TLCAN 2.0 incluye disposiciones que amenazan y debilitan laposibilidad de conseguir una adecuada atención en salud y medicamentos asequibles.
-
5-Dec-2018 Public Citizen
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts towards affordable health care and medicine.
-
26-Nov-2018 The Diplomat
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
-
19-Nov-2018 Peoples Dispatch
PHA4: Neoliberal policies and corporate takeover are the cause of the world health crisis
Multinational corporations are suing countries for using generic versions of life saving medicines.
-
12-Nov-2018 Public Eye
Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia
Swiss and Norwegians civil society groups addressed their serious concerns over TRIPS-plus provisions being included in the trade agreement under negotiation between the European Free Trade Association (EFTA) and Indonesia.
-
12-Nov-2018 Don’t trade our lives away
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
-
8-Nov-2018 IGJ
Indonesia-EFTA CEPA TRIPS-plus, threat for access to medicines and the right to health of millions of people in Indonesia
In many countries, the implementation of the TRIPS-plus measures has significantly increased the cost of medicines.
-
8-Nov-2018 The Guardian.pe.ca
Drugs costs impact health
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
-
9-Oct-2018 European Pharmaceutical Manufacturer
Trade and patent changes could increase healthcare costs by $100bn, CPHI annual report warns
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
-
5-Oct-2018 Financial Post
Canada ’caved’ on intellectual property provisions in USMCA trade deal, experts say
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
-
4-Oct-2018 El Salto Diario
NAFTA 2.0: otra muestra del Estado corporativo conducido por Trump
En la medianoche del domingo, y tras meses de fuertes tensiones diplomáticas, los gobiernos de los Estados Unidos y de Canadá adoptaron un nuevo acuerdo comercial preliminar, junto con México, que ahora se llamaría United States-Mexico-Canada Agreement (USMCA, el Acuerdo de los Estados Unidos con México y Canadá), reafirmando el papel hegemónico estadounidense. Este tipo de acuerdos provocan la precarización laboral, la bajada de salarios y daños ambientales irreversibles.
-
12-Sep-2018 IP Watch
Extended monopolies on biologic drugs – A warning to developing countries
The United States has throughout history been the principal demandeur of maximalist intellectual property, backed by a powerful pharmaceutical lobby.
-
28-Aug-2018 Pharmaceutical Commerce
Biologic drugs would get 10 years of data protection under revised US-Mexico trade deal
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.
-
27-Aug-2018 El Economista
TLCAN y la batalla por más acceso a la salud
Una pregunta para el doctor Jorge Alcocer -designado próximo secretario de Salud- y el equipo que llevará las riendas del Sector Salud durante el próximo gobierno en México: ¿tienen claro el probable impacto negativo sobre los precios de medicamentos resultado de la renegociación del TLCAN?.
-
2-Aug-2018 Asia Times
Dozens of grassroots groups want changes to ‘secret’ trade pact
While some states in East and Southeast Asia favor the 16-nation RCEP trade deal, many civil society groups say it lacks transparency and public participation.
-
23-Jul-2018 El Mostrador
TLC con la Unión Europea: Un peligro más allá del TPP
Aunque creíamos que con el TPP se había tocado fondo en cuanto a restringir el derecho a la salud de los chilenos, nos hemos sorprendido al conocer los mecanismos que incorpora la actualización del TLC con la Unión Europea y cuya propuesta ya está publicada en el sitio web de la comunidad.
-
20-Jul-2018 Bangkok Post
Trade deals putting health at risk
A leaked draft of the negotiating text has revealed some proposed harmful intellectual property provisions that could undermine access to price-lowering, generic medicines, and thus, life-saving treatment to millions of people.
-
16-Jul-2018 Chile Mejor sin TLC
Minuta, medicamentos y TLC con la UE
En la actualidad la industria farmacéutica busca extender los períodos en los cuales tiene exclusividad de mercado para un determinado medicamento.
